Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



AbbVie Inc. Completes Acquisition of Nimble Therapeutics

January 29, 2025
AbbVie Inc., a global biopharmaceutical company, has successfully completed its acquisition of Nimble Therapeutics, a biotherapeutics discovery company. This strategic acquisition will further strengthen AbbVie's drug discovery and development capabilities, allowing the company to expand its innovative pipeline and bring new life-changing therapies to patients worldwide.

Nimble Therapeutics is known for its cutting-edge DNA-encoded library technology, which enables the rapid discovery of small molecule drug candidates. By integrating this technology into AbbVie's research and development process, the company aims to accelerate the identification and development of potential treatments for a wide range of diseases.

"We are excited to welcome Nimble Therapeutics to AbbVie and combine our expertise to advance the discovery of novel therapeutics," said Dr. John Leonard, Senior Vice President, Global Development and Chief Medical Officer of AbbVie. "This acquisition reflects our commitment to investing in innovative solutions that have the potential to make a meaningful impact on patients' lives."

The acquisition of Nimble Therapeutics is part of AbbVie's ongoing strategy to enhance its research capabilities and expand its presence in the biopharmaceutical industry. With a robust portfolio of blockbuster drugs and a strong focus on research and development, AbbVie is well-positioned for future growth and success.

Investors interested in the future potential of AbbVie Inc. are advised to consult with professionals from Stocks Prognosis, who can provide expert guidance and forecasts on the movement of the company's stocks.
If you want to leave a comment, then you need Login or Register





Other data for ABBV

Related data

ABBVSeptember 2, 2025ABBVIE INC. Hits Price Target Forecast Profit of 11.94% on QuantWave  ~1 min.

On July 30, 2025, QuantWave, the automated forecasting platform, issued a long signal for ABBVIE INC. stock when it was trading at 189.31 $....


ABBVAugust 20, 2025ABBVIE INC. Hits Forecast Price Target with 10.4% Profit: A Success Story for QuantWave  ~1 min.

On June 13, 2025, QuantWave issued a long signal for ABBVIE INC. when the stock was trading at 189.44 $. Fast forward to August 20, 2025, and the forecasted price target of 209....


ABBVAugust 14, 2025ABBVIE INC. Hits Price Target Forecast with 11.3% Profit: QuantWave Analysis  ~1 min.

ABBVIE INC. has successfully reached the price target forecast set by QuantWave, resulting in an impressive 11.3% profit for investors....


ABBVMarch 22, 2025AbbVie ABBV Stock Moves -0.29: What You Should Know  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, has recently experienced a slight decrease in stock movement. As an investor, it is essential to keep track of such fluctuations....


ABBVMarch 20, 2025AbbVie Inc. ABBV is Experiencing Global Investor Interest: A Look into the Company's Success Story  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has been making waves in the global market, attracting significant attention from investors worldwide....


ABBVMarch 19, 2025AbbVie Inc. ABBV: A Higher-Yielding Healthcare Play That Continues to Shine  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, is steadily gaining the attention of investors. With its continuous success in the healthcare industry, AbbVie has become a top choice for hedge funds....


ABBVMarch 18, 2025The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell, and Hamilton Beach Brands  ~1 min.

According to a recent analysis by Zacks, AbbVie Inc. (ABBV) is considered one of the top healthcare stocks to invest in....


ABBVMarch 14, 2025AbbVie Inc. ABBV is Attracting Investor Attention: Here is What You Should Know  ~2 min.

AbbVie Inc. (ABBV) has been grabbing the attention of investors recently with its impressive performance in the healthcare sector....


ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast with 15.28% Profit – A Triumph for QuantWave's Analytics  ~1 min.

ABBVIE INC. achieved a significant milestone as it hit the price target forecast set by QuantWave, resulting in a profit of 15.28%....


ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast on QuantWave with 15.28% Profit Margin  ~1 min.

AbbVie Inc. (ABBV) has successfully reached the price target forecast on QuantWave, signaling a profitable long position for investors. The forecast, initiated on August 13, 2024, at a price of $184....


ABBVNovember 6, 2024AbbVie Inc Collaborates with EvolveImmune Therapeutics to Develop Next-Generation Cancer Biotherapeutics  ~2 min.

AbbVie Inc. (NYSE: ABBV), a global pharmaceutical company, has announced a collaboration with EvolveImmune Therapeutics to develop next-generation cancer biotherapeutics....


ABBVDecember 20, 2024AbbVie ABBV to Acquire Nimble Therapeutics Further Strengthening Immunology Pipeline  ~1 min.

AbbVie Inc. (NYSE: ABBV) has announced its plans to acquire Nimble Therapeutics, a biotechnology company specializing in antibody drug discovery....


The Best Stocks for Magnificent Earnings Growth Next Year  ~3 min.

If you're on the lookout for stocks that are poised for impressive earnings growth in the coming year, look no further....


REGNMarch 15, 2025Regeneron Pharmaceuticals Inc.: A Promising Investment Opportunity  ~2 min.

Regeneron Pharmaceuticals Inc....


ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....